Berggruen Holdings is an investment firm takes a long-term, value-oriented, often contrarian view. It prefers to build organically and through acquisitions, partnering with management, as opposed to quick, opportunistic exits. Depending on the opportunity and asset class, Berggruen Holdings is prepared to make relatively small investments as well as equity commitments of up to $100 million in any one transaction.

Berggruen Holdings

We're Acequia Capital, a company and partnership based in Seattle with expertise in tech investments. We're seasoned industry partners and systems thinkers in product strategy, business models, and market entry. We're in good company with founding teams in most industries, mainly in the US, UK, and Europe.

Acequia Capital (AceCap)

BACKED is the human-centric venture capital fund. We invest in exceptional founders, at Seed, in Europe. We provide founders with an extensive support system to catalyse their development as a company operators and leaders. Through our Founder Experience Platform and energetic portfolio community we help entrepreneurs across all areas of a startup: from talent management to business development, further fundraising and international expansion. Founded in 2015 by partners Andre de Haes and Alex Brunicki, we invest across sectors including BioTech, Blockchain, Financial Services, Advanced Manufacturing, and more. Investments to date include Hutch, Thought Machine, LabGenius, THIS, Enterprise Alumni, and many more.

BACKED VC

Kindred is an early stage venture capital fund based in London that practices equitable venture. Kindred aligns ambitions and achievements with the portfolio. In structure and in spirit. Every single founder that the company backs will become a co-owner of the fund.

Kindred Capital

System.One is a pre-seed venture capital fund. They are based in Berlin, but have a global mindset and reach. Their purpose is to invest in exceptional founders who combine early technical ideas with a bold mission and major potential impact. Pre-seed simply means They like to get in first – product and tech risk are core to what they do, not a problem they seek to eliminate.

System.One

TGM ventures mainly focuses on early stage internet companies including social media companies.

TGM ventures

Beast Ventures

Champion Hill Labs invests in private technology companies

Champion Hill Labs

Tiny VC

Felicis Ventures is a venture capital firm based in Menlo Park, California. The firm invests in seed through Series C stage companies across multiple sectors and industries reinventing core markets, as well as those creating frontier technologies. Felicis currently manages over $2B in capital across 8 funds. The firm is an early backer of more than 40 companies valued at $1B+. More than 90 of its portfolio companies have been acquired or gone public since the firm was founded by Aydin Senkut in 2006.

Felicis

Inovia Capital is a venture capital firm that works with founders to create influential and permanent businesses. The team leverages an operator mindset to provide founders with support, mentorship, and access to a worldwide network. Inovia manages over US$2.2B with operations in Montreal, Toronto, Calgary, San Francisco, and London.

Inovia Capital

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investment strategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Lux Capital

Obvious Ventures is a venture capital firm that invests in the early and growth stages. The firm was founded in 2014 and is based in San Francisco, California.

Obvious Ventures

Air Street Capital invests in AI-first technology and life science companies.

Air Street Capital

Gigafund makes long-term concentrated investments in founders who are capable of growing with their companies and impact over a period of decades.In order to keep housing affordable, we need millions of new homes. The cover is preparing to mass manufacture high-end, well-designed homes at a fraction of the cost of traditional housing. Last energy is creating clean, low-cost nuclear power to meet the growing energy demands and reverse the effects of climate change.

Gigafund

Atomico is an international investment firm that focuses on helping disruptive technology companies scale globally. It partners with technology founders at the Seed stage and beyond with a particular focus on Europe, leveraging deep operational experience to supercharge their growth. The company's team of founders, investors, and operational leaders have been responsible for global expansion, hiring, and marketing at companies from Skype, Google, and Twitter to Wise and Snowflake. It specializes in seed, startup, Series A, early venture, mid venture, late venture, emerging growth, and growth capital investments.   Atomico was founded in 2006 and is headquartered in London, England, with offices in Paris, Berlin, and Stockholm

Atomico

LabGenius

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.

<div>Based in the UK, Lab Genius uses a combination of AI, robotic automation, and synthetic biology to develop protein therapeutics. The company&rsquo;s smart robotic platform, EVA, is capable of designing, conducting, and learning from its own experiments to discover and characterize new molecules with a particular focus on antibody discovery for cancer and inflammatory diseases. This platform technology intelligently navigates the design space using an iterative process called &ldquo;active learning,&rdquo; significantly increasing the likelihood of identifying high-performing antibodies more quickly than conventional methods.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.</div>

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

<div>
 
 Based in the UK, Lab Genius uses a combination of AI, robotic automation, and synthetic biology to develop protein therapeutics. The company&rsquo;s smart robotic platform, EVA, is capable of designing, conducting, and learning from its own experiments to discover and characterize new molecules with a particular focus on antibody discovery for cancer and inflammatory diseases. This platform technology intelligently navigates the design space using an iterative process called &ldquo;active learning,&rdquo; significantly increasing the likelihood of identifying high-performing antibodies more quickly than conventional methods.
 
 
 Key customers and partnerships
 
 
 LabGenius has entered notable partnerships to enhance its research capabilities and leverage its ML-driven platform. In July 2021, the company announced a multi-year research collaboration with 
 <a href="https://labgeni.us/news-1/pressrelease-sanofi-atzg7">
 Ablynx
 </a>
 , a Sanofi company, to optimize drug candidates focused on inflammation. The company also partnered with 
 <a href="https://www.tillotts.com/news-events/pressrelease/tillotts-pharma-ag-and-labgenius-enter-development-agreement-in-inflammatory-bowel-diseases/">
 Tillots Pharma AG
 </a>
 in March 2019 to discover and develop durg candidates to treat inflammatory bowel diseases (IBD).
 
 
 Funding and financials
 
 
 In October 2022, LabGenius secured a 
 <a href="https://sp-edge.com/updates/13649">
 grant
 </a>
 from InnovateUK via its highly competitive GBP 25 million (USD 28 million) SMART program to advance the company&rsquo;s AI platform. In October 2020, the company raised USD 15 million in a 
 <a href="https://www.maddyness.com/uk/2020/10/30/labgenius-closes-15m-series-a-extension-led-by-atomico/">
 Series A
 </a>
 funding round led by Atomico to develop its platform and product portfolio.
 
</div>

<div>
 
 e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies.&nbsp;
 
 
 The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.
 
 
 Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/e-therapeutics-signs-research-collaboration-agreement-novo-nordisk/">
 Novo Nordisk
 </a>
 (December 2018), 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/collaboration-galapagos-discover-new-therapeutic-strategies-treatment-idiopathic-pulmonary-fibrosis-and-other-fibrotic-condition/">
 Galapagos
 </a>
 (June 2020), and 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/immuno-oncology-research-collaboration-iteos-therapeutics/">
 iTeos Therapeutics 
 </a>
 (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration.&nbsp;
 
 
 Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson&rsquo;s disease.&nbsp;
 
 
 Funding and financials
 
 
 In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange&rsquo;s public market for small and medium-sized growth companies, under the ticker symbol &ldquo;ETX&rdquo;. Further in 
 <a href="https://sp-edge.com/updates/13462">
 September 2022
 </a>
 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&amp;G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.
 
</div>

eTherapeutics

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

<div>
 
 Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris&rsquo;s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.
 
</div>

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

<div>
 
 LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.
 
</div>

<div>
 
 Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
 
</div>

Innovent Biologics

<div>
 
 ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
 
</div>

ADC Therapeutics

<div>
 
 Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor microenvironment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
 
</div>

Sirnaomics

<div>
 
 Sesen Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on their Targeted Protein Therapeutics (TPTs) platform. Their TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.
 
</div>

Sesen Bio

<div>
 
 ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
 
</div>

ACELYRIN

AL/ML used to identify potential drug targets, and support protein engineering and optimization

Companies that develop large molecules that can be used to replace or supplement deficient or malfunctioning proteins in the body

LabGenius

AI Drug Discovery

Key stats

Recent Updates

LabGenius receives InnovateUK grant to advance AI platform

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless